Celcuity (CELC) Set to Release Quarterly Earnings on Thursday

Celcuity (NASDAQ:CELC) is expected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($1.51) per share and revenue of $0.91 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28). On average, analysts expect Celcuity to post ($4.98) EPS for the current fiscal year and ($2.53) EPS for the next fiscal year.

Celcuity Price Performance

Shares of CELC stock opened at $69.72 on Wednesday. The business’s fifty day simple moving average is $76.72 and its 200-day simple moving average is $99.96. The company has a quick ratio of 8.93, a current ratio of 8.93 and a debt-to-equity ratio of 6.04. Celcuity has a 12-month low of $53.54 and a 12-month high of $151.02.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CELC. Needham & Company LLC lowered their price objective on Celcuity from $140.00 to $134.00 and set a “buy” rating for the company in a research report on Wednesday, September 30th. Craig Hallum reaffirmed a “buy” rating and set a $178.00 target price on shares of Celcuity in a research report on Wednesday, July 15th. JPMorgan Chase & Co. began coverage on Celcuity in a research note on Thursday, September 17th. They issued an “overweight” rating and a $157.00 price target for the company. Wall Street Zen downgraded Celcuity from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $177.00 price target on shares of Celcuity in a report on Monday, August 17th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Celcuity presently has a consensus rating of “Moderate Buy” and an average target price of $152.57.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company’s CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.